Immunovia Publishes Interim Report for January-March 2023
January-March 2023 · Net sales amounted to kSEK 520 (182) divided by sales of tests kSEK 379 (122) and royalties kSEK 141(60). · Net earnings were MSEK -51.7 (-44.1) and earnings per share before and after dilution were SEK -2.28 (-1.95). · Cash Flow from operating activities were MSEK -39.7 (-46.1). · Cash and equivalents at the end of the period amounted to MSEK 68.2 (239.8). · On January 17, the Company appointed Lara E. Sucheston-Campbell as Head of Clinical and Medical Affairs · On January 19, the Company announced that a process to re-align the Swedish operations